Product
Zoster Vaccine Recombinant, Adjuvanted
2 clinical trials
5 indications
Indication
Herpes ZosterIndication
Safety and TolerabilityIndication
SHINGRIX Vaccine Response RatesIndication
Chronic Lymphocytic LeukemiaIndication
small lymphocytic lymphomaClinical trial
A Phase I, Randomized, Observer Blind Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Zoster Vaccine (Adenovirus Vector) in Healthy Adults Aged 50-65 YearsStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients That Are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) TherapyStatus: Completed, Estimated PCD: 2020-09-09